Trials / Recruiting
RecruitingNCT06803823
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
A Phase 2a, Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-2020 | ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily. |
| DRUG | Placebo | Two ONO-2020 placebo tablets will be orally administered once daily |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
- First posted
- 2025-01-31
- Last updated
- 2025-12-17
Locations
38 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06803823. Inclusion in this directory is not an endorsement.